Liquidity (Details Narrative) - USD ($) |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
| Accumulated deficit | $ 55,004,411 | $ 33,276,489 | |
| Proceeds from sale of stock | 41,378,762 | $ 15,235,283 | |
| Cash on hand | 36,597,469 | $ 14,992,257 | |
| Cystic Fibrosis Foundation Therapeutics Inc [Member] | |||
| Milestone payment | $ 500,000 | ||
| Institutional Investors [Member] | October 26, 2017 [Member] | |||
| Number of common stock share sold | 4,650,000 | ||
| Purchase price per share | $ 7.00 | ||
| Proceeds from sale of stock | $ 32,550,000 | ||
| Institutional Investors [Member] | October 2017 Offering [Member] | October 26, 2017 [Member] | |||
| Number of common stock share sold | 4,650,000 | ||
| Purchase price per share | $ 7.00 | ||
| Proceeds from sale of stock | $ 30,397,000 | ||
| X | ||||||||||
- Definition Milestone payment. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|